Description: |
This trial seeks to determine whether multiple therapies, including chemotherapy, earlier in the disease will result in longer periods of progression-free survival (PSA progression and metastases). Eligibility includes: radical prostatectomy within 3 yrs; Gleason score 7-10; PSA = 2.0 ng/ml and = 0.2 ng/ml; rising PSA without evidence of metastatic disease; NO prior systemic or biologic therapy. |
Link: |
|
Site: |
Johns Hopkins Hospital |
Principal Investigator: |
Phuoc Tran, M.D. |
Overview
Content Tools